Alzheimer's: Page 6

Diadem wins CE-IVD Mark for Alzheimer's prognostic blood test
By LabPulse.com staff writers
The prognostic blood test can predict likely progression to Alzheimer's disease up to six years in advance of symptoms, according to the company. AlzoSure previously received breakthrough device designation by the U.S. Food and Drug Administration (FDA) in January.
February 28, 2022
2022 03 02 00 55 3488 Woman Dementia Alzheimer 400
SDx partners with I-Ally on Alzheimer's test
By LabPulse.com staff writers
The partnership's goal is to help caregivers get a diagnosis quickly for Alzheimer's disease in patients, as well as raising Alzheimer's awareness early in patients diagnosed with dementia.
February 24, 2022
2021 06 23 21 28 5659 Woman Dementia Alzheimer 400
Synaps Dx's Alzheimer's disease test gets payment code
By LabPulse.com staff writers
The Discern test is the first autopsy-validated, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's disease dementias to earn PLA codes 206U and 207U, Synaps Dx said.
November 8, 2021
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Diadem touts studies on Alzheimer's detection
By LabPulse.com staff writers
AlzoSure is a plasma-based biomarker designed to predict the likelihood that a patient will develop Alzheimer's. Using patented technology, the assay employs an antibody that binds to a conformational variant of the p53 protein, U-p53AZ, which is a protein that plays a key role in AD progression.
February 2, 2021
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Blood test shows promise in predicting course of Alzheimer's disease
By LabPulse.com staff writers
A team led by Klaus Gerwert, PhD, and Julia Stockmann, PhD, both of the Bochum Research Center for Protein Diagnostics in Bochum, Germany, analyzed blood samples taken from 203 patients at the Alzheimer Center Amsterdam. The researchers used a test developed at Ruhr-Universität Bochum called the Immuno-Infrared Sensor, which identifies misfolding of the amyloid-beta peptide (a biomarker for Alzheimer's disease).
January 6, 2021
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Tau Alzheimer's blood test gives PET a run for its money
By Emily Hayes
The study of 490 people included healthy controls and participants with subjective cognitive decline or mild cognitive impairment who were tested for tau phosphorylated at threonine 217 (p-tau-217). Various methods of early detection of Alzheimer's were compared for their value in the detection of preclinical disease.
November 9, 2020
2020 11 10 18 38 4846 Elderly Patient Ambulatory 400
C2N Diagnostics debuts blood test to ID Alzheimer's disease
By LabPulse.com staff writers
Samples from PrecivityAD are sent to the company's lab in St. Louis. Development of the test was supported by $2.8 million in funding from the Alzheimer's Drug Discovery Foundation over the past decade.
October 29, 2020
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Tau blood test shows promise for very early Alzheimer's detection
By Emily Hayes
One study was conducted at the lab of Dr. Randall Bateman, a Charles F. and Joanne Knight distinguished professor of neurology at Washington University in St. Louis. Researchers evaluated a mass spectrometry test for assessment of p-tau-217 and other tau fragments using small blood samples -- as small as 4 mL.
July 28, 2020
2020 07 29 20 05 8205 Biomarkers 400
Quanterix announces kit for Alzheimer's disease detection
By LabPulse.com staff writers
The test is designed to detect tau phosphorylated at threonine 181 (p-tau181), a biomarker for Alzheimer's disease found in cerebral spinal fluid, serum, and plasma. The company is positioning the test as a blood-based screening method to help identify patients with Alzheimer's disease prior to showing clinical symptoms. In addition to enabling earlier diagnosis, the test could also help differentiate Alzheimer's disease from other neurodegenerative disorders, according to the company.
June 1, 2020
2020 03 31 23 03 5810 Brain Dementia Leaves 400
FDA approves Avid's PET agent for tau pathology imaging
By LabPulse.com staff writers
Tauvid is indicated for adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. The PET radiopharmaceutical helps clinicians estimate the density and distribution of tau neurofibrillary tangles in the brain, which are a marker of Alzheimer's disease.
May 28, 2020
2019 02 13 19 24 5396 Fda Logo V2 400
Tau protein biomarker proves itself in Alzheimer's blood test
By Kate Madden Yee
The new test could make screening and diagnosis of the disease easier, wrote a team led by Dr. Kaj Blennow, PhD, of the University of Gothenburg. This protein is typically identified via cerebrospinal fluid testing or PET scans, both of which have their drawbacks.
April 28, 2020
2020 03 03 19 15 0064 Alzheimers Tau Tangles 400
Gene biomarker shows promise as alternative early Alzheimer's blood test
By Emily Hayes
The group evaluated extracellular RNA (exRNA) in plasma samples from 35 study participants who had confirmed Alzheimer's disease based on postmortem pathological brain examinations and who had been followed for 15 years prior to death. Of the total, nine had not been symptomatic and served as controls.
March 31, 2020
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Previous Page
Page 6 of 8
Next Page